These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12419098

  • 1. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.
    Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL, Pemirolast study group.
    J Ocul Pharmacol Ther; 2002 Oct; 18(5):475-88. PubMed ID: 12419098
    [Abstract] [Full Text] [Related]

  • 2. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [Abstract] [Full Text] [Related]

  • 3. A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.
    Gous P, Ropo A.
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):139-50. PubMed ID: 15117570
    [Abstract] [Full Text] [Related]

  • 4. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Study Group.
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
    Miyake-Kashima M, Takano Y, Tanaka M, Satake Y, Kawakita T, Dogru M, Asano-Kato N, Fukagawa K, Fujishima H.
    Jpn J Ophthalmol; 2004 Aug; 48(6):587-90. PubMed ID: 15592786
    [Abstract] [Full Text] [Related]

  • 6. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study.
    Shulman DG.
    Adv Ther; 2003 Aug; 20(1):31-40. PubMed ID: 12772816
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB, Turner D.
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
    Carr WW, Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI, Bepotastine Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group.
    Allergy Asthma Proc; 2013 Mar; 34(3):247-54. PubMed ID: 23484763
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 12. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.
    Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI, Bepotastine Besilate Ophthalmic Solutions Study Group.
    Allergy Asthma Proc; 2012 Jun; 33(3):265-74. PubMed ID: 22991696
    [Abstract] [Full Text] [Related]

  • 13. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E, Narvekar A, Gomes P, Adewale A, Torkildsen G.
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [Abstract] [Full Text] [Related]

  • 14. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 15. A pilot study of pemirolast in patients with seasonal allergic rhinitis.
    Tinkelman DG, Berkowitz RB.
    Ann Allergy; 1991 Feb; 66(2):162-5. PubMed ID: 1994787
    [Abstract] [Full Text] [Related]

  • 16. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL, Abelson MB, Gomes PJ.
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [Abstract] [Full Text] [Related]

  • 17. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
    Shulman DG, Amdahl L, Washington C, Graves A.
    Clin Ther; 2003 Apr; 25(4):1096-106. PubMed ID: 12809959
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M, Berger WE, Butrus S, Epstein AB, Irkec M.
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [Abstract] [Full Text] [Related]

  • 19. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M, Howes J, George M.
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [Abstract] [Full Text] [Related]

  • 20. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV, Minno G.
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.